1. From: A Recombinant Glycoprotein Vaccine for Herpes Simplex Type 2: Safety and Efficacy
Ann Intern Med. 1995;122(12): doi: /
Figure Legend:
Top.Bottom.Herpes simplex virus type 2 (HSV-2) neutralizing antibodies in persons with naturally acquired herpes simplex virus type 1 (HSV-1) and HSV-2 infection. One hundred thirty-three patients were seropositive for only HSV-2 by Western blot, and 249 patients were HSV-1-seropositive only. Herpes simplex virus type 2 neutralizing antibodies in patients 2 weeks after the third immunization with the 30- micrograms vaccine. Twenty-three patients were HSV-seronegative, and 15 were HSV-1-seropositive. Asterisk indicates the dilution at which there is 50% inhibition of cytolysis of the cell monolayer.
Date of download: 12/24/2017
Copyright © American College of Physicians. All rights reserved.